A detailed history of Virtus ETF Advisers LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 14,998 shares of EXEL stock, worth $505,432. This represents 0.19% of its overall portfolio holdings.

Number of Shares
14,998
Previous 14,998 -0.0%
Holding current value
$505,432
Previous $337,000 15.43%
% of portfolio
0.19%
Previous 0.17%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $27,418 - $31,988
-1,348 Reduced 8.25%
14,998 $337,000
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $47,439 - $56,283
2,352 Added 16.81%
16,346 $387,000
Q4 2023

Feb 15, 2024

SELL
$19.25 - $24.13 $42,484 - $53,254
-2,207 Reduced 13.62%
13,994 $335,000
Q3 2023

Nov 07, 2023

SELL
$19.04 - $22.74 $39,907 - $47,663
-2,096 Reduced 11.46%
16,201 $353,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $13,245 - $14,929
-729 Reduced 3.83%
18,297 $349,000
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $5,509 - $6,560
338 Added 1.81%
19,026 $369,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $80,200 - $93,227
5,361 Added 40.23%
18,688 $299,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $3,041 - $4,320
194 Added 1.48%
13,327 $209,000
Q2 2022

Aug 12, 2022

SELL
$17.44 - $23.16 $152,547 - $202,580
-8,747 Reduced 39.98%
13,133 $273,000
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $28,242 - $39,012
1,783 Added 8.87%
21,880 $400,000
Q3 2021

Nov 15, 2021

SELL
$16.3 - $21.14 $29,992 - $38,897
-1,840 Reduced 8.39%
20,097 $425,000
Q2 2021

Aug 10, 2021

SELL
$17.95 - $25.56 $152,485 - $217,132
-8,495 Reduced 27.91%
21,937 $400,000
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $17,039 - $20,932
830 Added 2.8%
30,432 $687,000
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $64,328 - $86,750
3,498 Added 13.4%
29,602 $594,000
Q3 2020

Nov 13, 2020

BUY
$20.67 - $26.94 $45,453 - $59,241
2,199 Added 9.2%
26,104 $638,000
Q2 2020

Aug 05, 2020

SELL
$16.46 - $27.42 $150,098 - $250,042
-9,119 Reduced 27.61%
23,905 $568,000
Q1 2020

May 14, 2020

SELL
$14.46 - $21.8 $40,285 - $60,734
-2,786 Reduced 7.78%
33,024 $569,000
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $9,574 - $11,938
632 Added 1.8%
35,810 $631,000
Q3 2019

Nov 12, 2019

SELL
$17.68 - $22.65 $104,541 - $133,929
-5,913 Reduced 14.39%
35,178 $622,000
Q2 2019

Aug 13, 2019

BUY
$18.93 - $24.75 $88,024 - $115,087
4,650 Added 12.76%
41,091 $878,000
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $149,430 - $188,770
7,624 Added 26.46%
36,441 $867,000
Q4 2018

Feb 05, 2019

SELL
$13.65 - $21.8 $150,614 - $240,541
-11,034 Reduced 27.69%
28,817 $567,000
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $43,150 - $60,905
2,719 Added 7.32%
39,851 $706,000
Q2 2018

Aug 10, 2018

BUY
$18.56 - $22.45 $49,239 - $59,559
2,653 Added 7.69%
37,132 $799,000
Q1 2018

May 14, 2018

SELL
$22.15 - $31.89 $45,252 - $65,151
-2,043 Reduced 5.59%
34,479 $764,000
Q4 2017

Feb 14, 2018

SELL
$24.23 - $30.93 $390,078 - $497,942
-16,099 Reduced 30.59%
36,522 $1.11 Million
Q2 2017

Aug 14, 2017

BUY
N/A
52,621
52,621 $1.3 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.8B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.